Fosamprenavir and Umeclidinium and vilanterol interaction
Fosamprenavir and Umeclidinium and vilanterol: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Fosamprenavir (Fosamprenavir Calcium) label · effective 2026-06-30
Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended.
From the Umeclidinium and vilanterol (Umeclidinium and Vilanterol Ellipta) label · effective 2024-11-22
Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone,…
• Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution.
Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the systemic exposure to vilanterol.
Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.4 ), Clinical Pharmacology ( 12.3 )] .
Inhibitors of Cytochrome P450 3A4 Vilanterol is a substrate of CYP3A4.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.